ArticleAntimicrobial agents and chemotherapy2011
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.Antiviral therapy · 2015Trial
- Novel Perspectives on the Design and Development of a Long-Acting Subcutaneous Raltegravir Injection for Treatment of HIV-In Vitro and In Vivo Evaluation.Pharmaceutics · 2023Article
- Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy.International journal of STD & AIDS · 2023Article
- A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.The Journal of antimicrobial chemotherapy · 2016Article
- Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.Antimicrobial agents and chemotherapy · 2016Article
- Article
- Barriers to a cure for HIV in women.Journal of the International AIDS Society · 2016Review
- Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.AIDS research and human retroviruses · 2015Observational
- Pharmacokinetics of antiretrovirals in mucosal tissue.Expert opinion on drug metabolism & toxicology · 2015Review
- Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.The Journal of antimicrobial chemotherapy · 2015Article
- Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Clinical pharmacokinetics · 2014Review
- Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Antimicrobial agents and chemotherapy · 2014Article
- Current perspectives in HIV post-exposure prophylaxis.HIV/AIDS (Auckland, N.Z.) · 2014Review
- A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Biomaterials · 2013Review
- Antiretroviral bioanalysis methods of tissues and body biofluids.Bioanalysis · 2013Review
- Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Antiviral therapy · 2013Article
- Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.Antiviral research · 2012Article
- Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.Antimicrobial agents and chemotherapy · 2012Article
- The use of preexposure treatments for HIV prophylaxis.HIV/AIDS (Auckland, N.Z.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infected women receiving a raltegravir-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median raltegravir concentrations were 235 ng/ml in BP and 93 ng/ml in CVF, with a CVF/BP ratio of approximately 2.3. This good penetration of raltegravir may contribute to the control of viral replication in the female genital tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.